Between
发表于 2025-3-25 04:14:28
http://reply.papertrans.cn/47/4625/462409/462409_21.png
忘川河
发表于 2025-3-25 08:53:27
Price Controls and Drug Affordability in India: Policy Options systems cannot rely entirely on market mechanisms for healthcare delivery. Price controls are a method of regulating drug prices for achieving health policy goals (Gray & Matsebula 2003). The governments use interventions from the supply side by controlling drug prices and/or from the demand side b
多嘴多舌
发表于 2025-3-25 14:26:13
Health Insurance in India 207). Most of the industrialised nations, except the US, and a small number of developing countries, provide health insurance programmes to cover most of their populations for substantial share of their health expenditure including pharmaceuticals. In the US, the public health insurance (Medicaid,
disciplined
发表于 2025-3-25 17:39:55
Broadening Access to Medicines and Healthcare in Indiae literature. This group of people is too rich to belong to the BPL families and too poor to belong to the middle-class Indians. The 300 million strong middle-class (M-class) Indians are the primary target for marketers and often acknowledged in the global media. The around 350. million estimated po
大沟
发表于 2025-3-25 20:07:26
http://reply.papertrans.cn/47/4625/462409/462409_25.png
过去分词
发表于 2025-3-26 01:34:05
http://reply.papertrans.cn/47/4625/462409/462409_26.png
束以马具
发表于 2025-3-26 05:37:09
Final Conclusions deals with the impact of the TRIPS agreement on the pharmaceutical industry and the access to medicines in India, acknowledging that the introduction of the TRIPS compliant regime from 1 January 2005 marked a major shift in India’s public policy on the protection of intellectual property rights (IP
promote
发表于 2025-3-26 08:43:53
http://reply.papertrans.cn/47/4625/462409/462409_28.png
Ostrich
发表于 2025-3-26 15:48:52
Broadening Access to Medicines and Healthcare in Indiaation in the BPL2 group and lower end of middle class group mostly get into irrecoverable debts in health crisis. India’s healthcare would be incomplete without addressing the needs of all three segments of the community.
召集
发表于 2025-3-26 17:48:57
Which Way Ahead?. Of all the intellectual property within TRIPS, the issue of pharmaceutical product patents has been the most controversial one (Alsegârd 2004). However, the TRIPS agreement is a set of rules on which all WTO members agreed. It may not suit the circumstances and interests of every member state; nevertheless, it is an agreed set of rules.